N-terminal telopeptide: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
No edit summary |
||
| Line 29: | Line 29: | ||
{{stub}} | {{stub}} | ||
<gallery> | <gallery> | ||
File:N-terminal telopeptide.svg|N-terminal telopeptide | File:N-terminal telopeptide.svg|N-terminal telopeptide | ||
</gallery> | </gallery> | ||
Latest revision as of 00:46, 17 March 2025
N-terminal telopeptide (or NTX) is a biomarker used in medicine to measure the rate of bone turnover. It can be tested in the blood or urine to monitor osteoporosis and assess the effectiveness of osteoporosis treatment.
Overview[edit]
The N-terminal telopeptide is released during bone resorption and can be detected in the blood or urine. It is a useful marker for the process of bone turnover, providing information about the balance between bone resorption and formation. It can be used to diagnose osteoporosis, monitor the effectiveness of treatment, and predict future bone loss.
Clinical Use[edit]
NTX can be used to monitor the effectiveness of osteoporosis treatment. If the levels of NTX decrease, it suggests that the treatment is effective. It can also be used to predict the risk of fractures in postmenopausal women. High levels of NTX are associated with a higher risk of fractures.
Testing[edit]
NTX is measured in the urine or blood. The test is non-invasive and can be done at home. The results are usually available within a few days. The test is not affected by food intake and can be performed at any time of the day.
Limitations[edit]
While NTX is a useful marker of bone turnover, it is not a diagnostic test for osteoporosis. The diagnosis of osteoporosis is made based on bone mineral density measurements. Furthermore, NTX levels can be affected by other factors such as kidney function and vitamin D levels.


